Transthyretin Amyloid Cardiomyopathy (ATTR-CM) research hub
4 indexed studies · 3 currently recruiting
- recruiting
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
This study looks at how a new medicine, Acoramidis, works for people in their everyday lives who have a serious heart condition called ATTR-CM. It will help us understand who uses it, how it's used, and if it improves their health and quality of life.
Germany - active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM
This study is testing two medicines, eplontersen and ALXN2220, to see if they are safe and help adults with a heart condition called ATTR-CM. Participants will take eplontersen along with either ALXN2220 or an inactive substance (placebo).
United States · Canada · China - recruitingPHASE3
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
This study looks at a new medicine called Coramitug for heart failure caused by a condition called ATTR amyloidosis. It aims to see if Coramitug can reduce serious heart problems. People will either get the medicine or a dummy treatment, alongside their usual care.
United States · Argentina · Australia - not yet recruitingPHASE3
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
This study looks at the long-term safety and effectiveness of a new medicine, ALXN2220, for adults with a heart condition called Transthyretin Amyloid Cardiomyopathy (ATTR-CM). It's for people who have already taken part in an earlier study for this medicine.
United States · Argentina · Australia